Zhou Xu1, Xingruo Zeng1, Jiawei Xu1, Derek Xu1, Jingxia Li1, Honglei Jin1, Guosong Jiang1, Xiaosi Han1, Chuanshu Huang1. 1. Nelson Institute of Environmental Medicine, New York University School of Medicine, Tuxedo, New York (Z.X., X.Z., J.X., D.X., J.L., H.J., G.J., C.H.); Department of Neurosurgery, Renmin Hospital of Wuhan University, Wuhan, China (Z.X.); Division of Neuro-Oncology, Department of Neurology, University of Alabama, Birmingham, Alabama (X.H.).
Abstract
BACKGROUND: Glioblastoma (GBM) is the most common malignant brain tumor, and glioma stem cells (GSCs) are considered a major source of treatment resistance for glioblastoma. Identifying new compounds that inhibit the growth of GSCs and understanding their underlying molecular mechanisms are therefore important for developing novel therapy for GBM. METHODS: We investigated the potential inhibitory effect of isorhapontigenin (ISO), an anticancer compound identified in our recent investigations, on anchorage-independent growth of patient-derived glioblastoma spheres (PDGS) and its mechanism of action. RESULTS: ISO treatment resulted in significant anchorage-independent growth inhibition, accompanied with cell cycle G0-G1 arrest and cyclin D1 protein downregulation in PDGS. Further studies established that cyclin D1 was downregulated by ISO at transcription levels in a SOX2-dependent manner. In addition, ISO attenuated SOX2 expression by specific induction of miR-145, which in turn suppressed 3'UTR activity of SOX2 mRNA without affecting its mRNA stability. Moreover, ectopic expression of exogenous SOX2 rendered D456 cells resistant to induction of cell cycle G0-G1 arrest and anchorage-independent growth inhibition upon ISO treatment, whereas inhibition of miR-145 resulted in D456 cells resistant to ISO inhibition of SOX2 and cyclin D1 expression. In addition, overexpression of miR-145 mimicked ISO treatment in D456 cells. CONCLUSIONS: ISO induces miR-145 expression, which binds to the SOX2 mRNA 3'UTR region and inhibits SOX2 protein translation. Inhibition of SOX2 leads to cyclin D1 downregulation and PDGS anchorage-independent growth inhibition. The elucidation of the miR-145/SOX2/cyclin D1 axis in PDGS provides a significant insight into understanding the anti-GBM effect of ISO compound.
BACKGROUND:Glioblastoma (GBM) is the most common malignant brain tumor, and glioma stem cells (GSCs) are considered a major source of treatment resistance for glioblastoma. Identifying new compounds that inhibit the growth of GSCs and understanding their underlying molecular mechanisms are therefore important for developing novel therapy for GBM. METHODS: We investigated the potential inhibitory effect of isorhapontigenin (ISO), an anticancer compound identified in our recent investigations, on anchorage-independent growth of patient-derived glioblastoma spheres (PDGS) and its mechanism of action. RESULTS:ISO treatment resulted in significant anchorage-independent growth inhibition, accompanied with cell cycle G0-G1 arrest and cyclin D1 protein downregulation in PDGS. Further studies established that cyclin D1 was downregulated by ISO at transcription levels in a SOX2-dependent manner. In addition, ISO attenuated SOX2 expression by specific induction of miR-145, which in turn suppressed 3'UTR activity of SOX2 mRNA without affecting its mRNA stability. Moreover, ectopic expression of exogenous SOX2 rendered D456 cells resistant to induction of cell cycle G0-G1 arrest and anchorage-independent growth inhibition upon ISO treatment, whereas inhibition of miR-145 resulted in D456 cells resistant to ISO inhibition of SOX2 and cyclin D1 expression. In addition, overexpression of miR-145 mimicked ISO treatment in D456 cells. CONCLUSIONS:ISO induces miR-145 expression, which binds to the SOX2 mRNA 3'UTR region and inhibits SOX2 protein translation. Inhibition of SOX2 leads to cyclin D1 downregulation and PDGS anchorage-independent growth inhibition. The elucidation of the miR-145/SOX2/cyclin D1 axis in PDGS provides a significant insight into understanding the anti-GBM effect of ISO compound.
Authors: Roberto Ferrarese; Griffith R Harsh; Ajay K Yadav; Eva Bug; Daniel Maticzka; Wilfried Reichardt; Stephen M Dombrowski; Tyler E Miller; Anie P Masilamani; Fangping Dai; Hyunsoo Kim; Michael Hadler; Denise M Scholtens; Irene L Y Yu; Jürgen Beck; Vinodh Srinivasasainagendra; Fabrizio Costa; Nicoleta Baxan; Dietmar Pfeifer; Dominik von Elverfeldt; Rolf Backofen; Astrid Weyerbrock; Christine W Duarte; Xiaolin He; Marco Prinz; James P Chandler; Hannes Vogel; Arnab Chakravarti; Jeremy N Rich; Maria S Carro; Markus Bredel Journal: J Clin Invest Date: 2014-05-27 Impact factor: 14.808
Authors: Rosaria Maria Rita Gangemi; Fabrizio Griffero; Daniela Marubbi; Marzia Perera; Maria Cristina Capra; Paolo Malatesta; Gian Luigi Ravetti; Gian Luigi Zona; Antonio Daga; Giorgio Corte Journal: Stem Cells Date: 2009-01 Impact factor: 6.277
Authors: Gregory K Friedman; Catherine P Langford; Jennifer M Coleman; Kevin A Cassady; Jacqueline N Parker; James M Markert; G Yancey Gillespie Journal: J Neurooncol Date: 2009-06-12 Impact factor: 4.130
Authors: Abhinav K Jain; Kendra Allton; Michelina Iacovino; Elisabeth Mahen; Robert J Milczarek; Thomas P Zwaka; Michael Kyba; Michelle Craig Barton Journal: PLoS Biol Date: 2012-02-28 Impact factor: 8.029
Authors: Xiaosi Han; Wenbin Zhang; Xiuhua Yang; Crystal G Wheeler; Catherine P Langford; Lu Wu; Natalia Filippova; Gregory K Friedman; Qiang Ding; Hassan M Fathallah-Shaykh; G Yancey Gillespie; L Burt Nabors Journal: Int J Oncol Date: 2014-05-09 Impact factor: 5.650
Authors: C Zhou; C Huang; J Wang; H Huang; J Li; Q Xie; Y Liu; J Zhu; Y Li; D Zhang; Q Zhu; C Huang Journal: Oncogene Date: 2017-03-06 Impact factor: 9.867